Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novocell, a stem cell engineering company, has received a new US patent with claims covering human definitive endoderm cells, which the company is developing for use as a cell therapy for diabetes, but also other endoderm lineage-derived tissues and organs such as lungs, intestine, liver, thymus and thyroid.
Subscribe to our email newsletter
Fred Middleton, chairman and acting CEO of Novocell, said: “This composition patent is a milestone achievement for Novocell and is the culmination of extensive research that opened the door to the endoderm lineage.
“The efficient production of endoderm represents the first critical step in the creation of a renewable islet source derived from hES cells that is targeted at restoring normal glucose regulation in diabetic patients.”